Conference leader Q1 Productions prepares to host its event* examining the challenges faced, strategies employed and future ahead for today's pharmaceutical public relations professional. Held over January 30 and 31, 2012 in Cambridge, MA, this conference will bring together various insights from the likes of Pfizer, Bristol-Myers Squibb and Janssen Pharmaceuticals to speak to achieving most effective brand communications in industry undertakings like product crisis management and corporate social responsibility. As high-profile incidents within industry continue to make headlines, requiring the deft handling of pharmaceutical PR executives as they release and react to information, the stakes are only growing to distribute the best messages. Pharmaceutical companies are constantly strategizing to maintain and augment company reputation and investor relations.
Microbes causing infectious diseases are associated with more than 30% off all cancers. In the recent years several prophylactic vaccines that have been developed have proved to be an important advancement, impacting the incidence of liver cancer and cervical cancer. Prophylactic vaccines and their future position on the vaccine market is one of the topics that will be presented at the 2nd Global Vaccine Forum in Vienna. This meeting will be inducted with a free one-day workshop on 29th February 2012 that will go deeper into the technical aspects of combination vaccine development and also immunization programmes. Attendees of this meeting will also be able to get ready-to-use knowledge from other crucial topics such as: influenza vaccines combination vaccines HPV vaccines allergy vaccines cancer vaccine biodefense The presentations will be delivered by professional leaders from all related sectors - industry, governmental, academic, scientific.
Anti-counterfeiting, packaging safely via redesign, 2D barcoding integrity and artwork management updates are among the major themes of Fleming Europe's 2nd Annual Pharma Packaging & Labeling Compliance Conference which is once again bringing you three days of ground-breaking debate and pioneering case studies from top industry, regulatory and association experts: Michael Nieuwesteeg from Netherlands Packaging Centre (NVC) and World Packaging Organization will focus on the role of packaging innovation in ensuring a sustainable future of medicine. Janice Kite from GS1 Global Office will introduce updates on standards development and implementation. She will offer special insight on GS1 Standards for Healthcare: process and technical standards and she will also show how the standards assist in compliance to the Directive for Falsified Medicines.
With declining R&D costs, prioritizing a portfolio of successful projects has become essential within the pharmaceutical industry. Lifecycle management approaches must be implemented throughout a products developmental and market period to ensure an increase in profit. Ultimately, the success of pharmaceutical companies relies on crucial project portfolio decisions and understanding of a product's lifecycle. Don't miss out on this fantastic opportunity to network with experts in the field that includes: Tony Ellery, Managing Director, Ellery Pharma Consulting, Former Global Head LCM in Portfolio Management, Novartis‚ ® Kimber Hardy, Head of Valuation and Analysis, Merck Serono Tim Harris, Director, Respiratory & Immuno-inflammation Portfolio Management, GlaxoSmithKline‚ ® Shafique Virani, Global Head CNS Business Development, F.
With the increasing demand for eligible study patient populations as well as the need for more cost-efficient clinical development programs, the CEE and CIS region represents an attractive location for pharma companies to conduct clinical trials. However, there are a number of challenges that all industry stakeholders need to overcome in order to conduct clinically and commercially successful trials. Fleming Europe once again invites you to attend two days of ground-breaking discussion and pioneering case-studies from top pharma industry, regulatory and clinical experts at the 5th Annual CEE & CIS Clinical Trials Forum. We will be discussing key issues such as: Revealing the differences between CEE & CIS and the benefits of clinical trials in CEE with Jiri Kopriva, Head of Medical Affairs at Janssen-Cilag, Czech Republic Moldovan Perspectives on Regulatory Concerns with Clinical Trials with Lucia Turcan, Head of Drug Evaluation-Authorization Department at the Medicines Agency of Moldova Overview of Conducting Clinical Trials in the Russian Federation Ukraine - Assessment of the Progress in the Recent Years This conference is a unique opportunity for professionals to meet and discuss the latest pharma developments, as well as network with their peers.